NorthWest Biotherapeutics Inc (NWBO)

[dennisdave]

The recent MIA update is important it removes a site-level GMP hurdle. But it does not automatically mean that all remaining steps required for MHRA approval (if indeed based on manual production) have been completed. A Manufacturer’s Licence (MIA) confirms that a facility is authorised to operate to GMP standards for certain activities. It does not by itself confirm that the product-specific manufacturing process, controls, validation, and commercial intent have all been fully accepted within the MA dossier.

For ATMPs in particular, MHRA approval still depends on: product-specific CMC acceptance, consistency of the intended commercial manufacturing route in the MA, closure of any outstanding dossier-level questions or internal review points.

So while the MIA update is a necessary and positive step, it does not formally exclude the possibility that additional product-level or dossier-level steps are still required before an MA decision can be taken.